Michael S. Chang MD , Jordan T. Said MD , Elliot H. Akama-Garren PhD , Nicole Trepanowski MD , Ai-Tram N. Bui MD , Anita Giobbie-Hurder MS , Nicole R. LeBoeuf MD, MPH , Rebecca I. Hartman MD, MPH
{"title":"在接受免疫检查点抑制剂治疗的转移性黑色素瘤患者中,NRAS肿瘤突变与皮肤不良事件发生率降低相关。","authors":"Michael S. Chang MD , Jordan T. Said MD , Elliot H. Akama-Garren PhD , Nicole Trepanowski MD , Ai-Tram N. Bui MD , Anita Giobbie-Hurder MS , Nicole R. LeBoeuf MD, MPH , Rebecca I. Hartman MD, MPH","doi":"10.1016/j.jdin.2024.11.004","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":34410,"journal":{"name":"JAAD International","volume":"18 ","pages":"Pages 165-167"},"PeriodicalIF":0.0000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11742302/pdf/","citationCount":"0","resultStr":"{\"title\":\"NRAS tumor mutations are associated with reduced odds of dermatologic adverse events in patients with metastatic melanoma receiving immune checkpoint inhibitors\",\"authors\":\"Michael S. Chang MD , Jordan T. Said MD , Elliot H. Akama-Garren PhD , Nicole Trepanowski MD , Ai-Tram N. Bui MD , Anita Giobbie-Hurder MS , Nicole R. LeBoeuf MD, MPH , Rebecca I. Hartman MD, MPH\",\"doi\":\"10.1016/j.jdin.2024.11.004\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":34410,\"journal\":{\"name\":\"JAAD International\",\"volume\":\"18 \",\"pages\":\"Pages 165-167\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11742302/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"JAAD International\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2666328724001822\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"JAAD International","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666328724001822","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
NRAS tumor mutations are associated with reduced odds of dermatologic adverse events in patients with metastatic melanoma receiving immune checkpoint inhibitors